Virax Biolabs Group Ltd (VRAX) Total Current Liabilities (2021 - 2025)

Virax Biolabs (VRAX) has 5 years of Total Current Liabilities data on file, last reported at $673207.0 in Q1 2025.

• In Q1 2025, Total Current Liabilities rose 298.7% year-over-year to $673207.0; the TTM figure through Mar 2025 stood at $673207.0 (up 298.7% YoY), while the FY2025 annual figure was $673207.0, up 298.7% from the prior year.
• Total Current Liabilities advanced to $673207.0 in Q1 2025, from $168849.0 in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.2 million in Q1 2022 and bottomed at $168849.0 in Q1 2024.
• A 5-year average of $773461.2 and a median of $871435.0 in 2021 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities sank 81.41% — and 2025, when it jumped 298.7%.
• Year by year, Total Current Liabilities stood at $871435.0 in 2021, then soared by 42.92% to $1.2 million in 2022, then slipped by 27.06% to $908401.0 in 2023, then sank by 81.41% to $168849.0 in 2024, then jumped by 298.7% to $673207.0 in 2025.
• The last three Total Current Liabilities figures came in at $673207.0 (Q1 2025), $168849.0 (Q1 2024), and $908401.0 (Q1 2023), per Business Quant data.

Peer Comparison